137 related articles for article (PubMed ID: 17683579)
1. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.
Zhang X; Zhang J; Wang L; Wei H; Tian Z
BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579
[TBL] [Abstract][Full Text] [Related]
2. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
Njatcha C; Farooqui M; Kornberg A; Johnson DE; Grandis JR; Siegfried JM
Mol Cancer Ther; 2018 Sep; 17(9):1917-1926. PubMed ID: 29891486
[TBL] [Abstract][Full Text] [Related]
3. Enhancing or eliminating signals for cell survival to treat disease.
Tweardy DJ; Jing N
Trans Am Clin Climatol Assoc; 2006; 117():33-51; discussion 51-2. PubMed ID: 18528463
[TBL] [Abstract][Full Text] [Related]
4.
Wang W; Song J; Lu N; Yan J; Chen G
Nutr Res Pract; 2023 Dec; 17(6):1070-1083. PubMed ID: 38053828
[TBL] [Abstract][Full Text] [Related]
5. Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells.
He X; Fu J; Lyu W; Huang M; Mo J; Cheng Y; Xu Y; Zheng L; Zhang X; Qi L; Zhang L; Zheng Y; Huang M; Ni L; Lu J
Chin J Nat Med; 2023 Nov; 21(11):842-851. PubMed ID: 38035939
[TBL] [Abstract][Full Text] [Related]
6. Targeting c-Myc with decoy oligodeoxynucleotide-loaded polycationic nanoparticles inhibits cell growth and induces apoptosis in cancer stem-like cells (NTERA-2).
Ghorbani R; Gharbavi M; Keshavarz B; Madanchi H; Johari B
Mol Biol Rep; 2024 May; 51(1):623. PubMed ID: 38710891
[TBL] [Abstract][Full Text] [Related]
7. The decoy oligodeoxynucleotide against HIF-1α and STAT5 ameliorates atopic dermatitis-like mouse model.
Gwon MG; Leem J; An HJ; Gu H; Bae S; Kim JH; Park KK
Mol Ther Nucleic Acids; 2023 Dec; 34():102036. PubMed ID: 37799329
[TBL] [Abstract][Full Text] [Related]
8. Dual radiosensitization and anti-STAT3 anti-proliferative strategy based on delivery of gold nanoparticle - oligonucleotide nanoconstructs to head and neck cancer cells.
Zhang S; Gupta S; Fitzgerald TJ; Bogdanov AA
Nanotheranostics; 2018; 2(1):1-11. PubMed ID: 29291159
[TBL] [Abstract][Full Text] [Related]
9. Transfection of Vein Grafts with Early Growth Response Factor-1 Oligodeoxynucleotide Decoy: Effects on Stem-Cell Genes and Toll-like Receptor-Mediated Inflammation.
Mylonas KS; Peroulis M; Kapelouzou A
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958848
[TBL] [Abstract][Full Text] [Related]
10. Novel 1,3,4-oxadiazole Targets STAT3 Signaling to Induce Antitumor Effect in Lung Cancer.
Malojirao VH; Girimanchanaika SS; Shanmugam MK; Sherapura A; Dukanya ; Metri PK; Vigneshwaran V; Chinnathambi A; Alharbi SA; Rangappa S; Mohan CD; Basappa ; Prabhakar BT; Rangappa KS
Biomedicines; 2020 Sep; 8(9):. PubMed ID: 32967366
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer-Drug Carriers Matter.
Molenda S; Sikorska A; Florczak A; Lorenc P; Dams-Kozlowska H
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067351
[TBL] [Abstract][Full Text] [Related]
12. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.
De Rubis G; Paudel KR; Corrie L; Mehndiratta S; Patel VK; Kumbhar PS; Manjappa AS; Disouza J; Patravale V; Gupta G; Manandhar B; Rajput R; Robinson AK; Reyes RJ; Chakraborty A; Chellappan DK; Singh SK; Oliver BGG; Hansbro PM; Dua K
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2793-2833. PubMed ID: 37991539
[TBL] [Abstract][Full Text] [Related]
13. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
[TBL] [Abstract][Full Text] [Related]
14. Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.
Parakh S; Ernst M; Poh AR
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944848
[TBL] [Abstract][Full Text] [Related]
15. Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.
Kong R; Bharadwaj U; Eckols TK; Kolosov M; Wu H; Cruz-Pavlovich FJS; Shaw A; Ifelayo OI; Zhao H; Kasembeli MM; Wong STC; Tweardy DJ
Pharmacol Res; 2021 Jul; 169():105637. PubMed ID: 33932608
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies.
Morgan EL; Macdonald A
Viruses; 2020 Sep; 12(9):. PubMed ID: 32899142
[TBL] [Abstract][Full Text] [Related]
17. Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides.
Johari B; Rezaeejam H; Moradi M; Taghipour Z; Saltanatpour Z; Mortazavi Y; Nasehi L
Mol Biol Rep; 2020 Sep; 47(9):6793-6805. PubMed ID: 32865703
[TBL] [Abstract][Full Text] [Related]
18. Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges.
Arshad S; Naveed M; Ullia M; Javed K; Butt A; Khawar M; Amjad F
Genet Mol Biol; 2020; 43(1):e20180160. PubMed ID: 32167126
[TBL] [Abstract][Full Text] [Related]
19. Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells.
Bigdelou Z; Mortazavi Y; Saltanatpour Z; Asadi Z; Kadivar M; Johari B
Mol Biol Rep; 2020 Mar; 47(3):1859-1869. PubMed ID: 32016633
[TBL] [Abstract][Full Text] [Related]
20. Natural Sesquiterpene Lactones Enhance Chemosensitivity of Tumor Cells through Redox Regulation of STAT3 Signaling.
Butturini E; Carcereri de Prati A; Boriero D; Mariotto S
Oxid Med Cell Longev; 2019; 2019():4568964. PubMed ID: 31781335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
